VDPHL01 is an investigational, non-hormonal, oral drug that Veradermics is testing for male and female pattern hair loss. Veradermics describes it as a proprietary, non-hormonal approach being evaluated in a national Phase 2/3 clinical program.

If ultimately approved, it could become the first FDA-approved oral therapy designed specifically for pattern hair loss that does not work by shifting hormones. That is the headliner and it is the reason people are watching this program closely. Veradermics LIVE

On the company’s clinical-trials page, Veradermics says it is enrolling a Phase 2/3 trial for VDPHL01 for pattern hair loss and directs interested participants to a site-finder. The positioning is consistent across their pages: non-hormonal, oral, being tested in a late-stage program.

The formal study listings add detail, ClinicalTrials.gov shows an ongoing randomized, double-blind, placebo-controlled trial in men aged 18 to 65 with AGA (NCT06724614). There is also a registered study in women with AGA (NCT07146022). These entries reinforce that VDPHL01 is being evaluated in controlled settings for both sexes, with the male study described as multicenter and double-blind. ClinicalTrials.gov

Third-party trial registries and listings echo that framing and add some color, like the 8.5 mg tablet dose and a 13-month visit schedule in the male study. As always with aggregator sites, treat the granular numbers as descriptive rather than definitive until they match what the sponsor publishes, but they are consistent with a long, well-controlled efficacy and safety readout. MedPath

Funding and program scale matter too. Veradermics announced a 75 million dollar Series B round in late 2024, explicitly tied to initiating a Phase 2/3 program with around 480 patients across roughly 44 U.S. sites, with the company having aimed for Phase 2 topline data in the first half of 2025.

That target date is in the past now, but no peer-reviewed or FDA-filed top-line readout has been posted publicly as of mid-October 2025 on the company’s news page. So for now we rely on the live trial listings and past press disclosures. Business Wire

Bottom line on the “what”: a purpose-built, oral, non-hormonal candidate for AGA in a controlled Phase 2/3 program, with male and female trials registered and a sizable late-stage plan in motion. ClinicalTrials.gov

Why a non-hormonal oral matters in AGA

Most current “workhorse” drugs for AGA either modulate androgen signaling (finasteride, dutasteride) or work through follicle-level vasodilatory and cell-cycle pathways (minoxidil).

Finasteride blocks 5-alpha-reductase, which reduces conversion of testosterone to dihydrotestosterone (DHT). That mechanism is effective for many men but is, by definition, hormonal and can bring sexual or mood side effects in a minority of users. The FDA label and independent reviews lay out the efficacy and known risks. FDA Access Data

Minoxidil is mechanistically different. It is not anti-androgenic. Topical 5 % has strong evidence of improving hair counts and regrowth versus 2 % and versus placebo over 48 weeks, and oral minoxidil has become a popular off-label option.

A recent randomized trial found that 5 mg oral daily did not outperform twice-daily 5 % topical over 24 weeks in men, which is a useful benchmark when thinking about what any new oral needs to beat. PubMed

If VDPHL01 can deliver minoxidil-like or finasteride-like efficacy with a side-effect profile that avoids hormonal issues, it fills a real gap. That is the clinical and commercial thesis Veradermics is pursuing. The company’s pages are careful here: they emphasize “non-hormonal oral” and do not publicly disclose the exact mechanism of action.

What we know about the VDPHL01 clinical program

Study structure

The male study (NCT06724614) is described as multicenter, randomized, double-blind, and placebo-controlled. The female study (NCT07146022) mirrors that strategy in women.

Trials like these typically use a mix of objective hair counts in target areas (non-vellus hair count per cm² measured by standardized macrophotography) and global assessments by investigators and patients, assessed over many months to capture hair-cycle dynamics. The listings and third-party summaries mention an 8.5 mg tablet and a visit schedule over roughly 13 months for the male cohort. ClinicalTrials.gov

Scale and timing

The company’s financing releases reference a Phase 2/3 program with about 480 participants at about 44 sites, with prior guidance of a first-half-2025 topline for Phase 2.

As of today, there is no company-hosted topline PDF or peer-reviewed paper publicly linked from the Veradermics news page, and ClinicalTrials.gov does not show posted results yet. That means independent comparisons to legacy drugs must be framed as “pending” rather than “proven.” Business Wire

Any early signals?

There has been online chatter and some trade coverage around meeting posters and “early Phase 2 signals,” including claims of visible regrowth by two to four months and speculation about modified-release properties.

Treat these as interesting but preliminary. They are not a substitute for a peer-reviewed manuscript or FDA-grade top-line. Until Veradermics releases full Phase 2 data or posts results to ClinicalTrials.gov, the conservative reading is that efficacy remains to be confirmed in larger, longer cohorts. MedPath

Efficacy of VDPHL01 in the treatment of AGA: what can we say today?

Short version: it is promising enough to fund a large Phase 2/3 program, but definitive efficacy is not established publicly yet.

Longer version:

1. Endpoint expectations. Modern AGA trials often key on non-vellus hair counts in a target area at 24 to 26 weeks, plus global photographic assessments and patient-reported outcomes out to 48 to 52 weeks. That is how finasteride and minoxidil were evaluated historically. Expect VDPHL01’s pivotal readouts to be judged against similar measures. FDA Access Data
2. Comparability bar. For orientation, finasteride 1 mg showed a roughly 100-plus hair advantage versus placebo in a 5.1 cm² circle at 12 months, maintained through 24 months in extension, and increased anagen counts at 48 weeks in detailed scalp unit analyses. Topical 5 % minoxidil outperformed 2 % and placebo over 48 weeks in men. These are the effect sizes any new therapy must match or beat to be considered a category peer. FDA Access Data
3. What is known for VDPHL01. The sponsor says non-hormonal, oral, and late-stage. ClinicalTrials.gov confirms controlled studies in men and women. A 2024 press release sets scale and timing, and third-party trackers repeat those numbers. There is no peer-reviewed efficacy dataset in the public domain as of Oct 13, 2025. That means we cannot quote mean hair count deltas, responder rates, or time-to-onset from an authoritative paper yet. ClinicalTrials.gov

Bottom line on efficacy: we have reason to be optimistic given the investment and trial design, but the efficacy verdict awaits fully reported Phase 2/3 data. Anything stronger would be speculation. Business Wire

Is VDPHL01 better than minoxidil 5 % or finasteride?

Right now, there is no head-to-head, peer-reviewed study that proves VDPHL01 is superior to either 5 % minoxidil or 1 mg finasteride.

Some online summaries and conference-season buzz hint at early improvements, but those are not the same as a published head-to-head trial or a randomized superiority claim. The fairest, evidence-based answer is:

• Versus finasteride: Unknown. Finasteride’s efficacy is well documented in large, controlled trials and codified on the FDA label. We do not yet have published VDPHL01 data that match that level of detail. FDA Access Data
• Versus minoxidil 5 %: Unknown. Topical 5 % is proven versus 2 % and placebo. Oral minoxidil at 5 mg daily did not beat topical 5 % at 24 weeks in one randomized trial, which shows how high the bar is for any oral entrant claiming convenience and potency. Until VDPHL01 releases hard numbers, “better than minoxidil” remains unproven. PubMed

If the sponsor publishes Phase 2 data that show large, early gains in non-vellus hair count and strong investigator global assessments with a friendly side-effect profile, that will change this answer. At present, the cautious stance is appropriate. Business Wire

Safety and side effects: what we know and do not know

Veradermics emphasizes that VDPHL01 is non-hormonal, which is intended to avoid hormone-related adverse effects sometimes associated with 5-alpha-reductase inhibitors. That is a design goal, not a guarantee.

The only safety profile that matters in the end is what emerges from large randomized cohorts, long exposure, and real patients. The Phase 2/3 program is built to gather that information. Veradermics LIVE

What we can say today:

• Trial safeguards. The male study is double-blind and placebo-controlled with a long follow-up, which is the right structure to surface both common and time-linked adverse events. The female study is similarly structured. ClinicalTrials.gov
• Mechanism transparency. The exact mechanism has not been publicly detailed on official pages. Without mechanism and exposure-response data, it is premature to assume side-effect neutrality. Non-hormonal does not mean side-effect-free. That is true for any new oral drug. Veradermics LIVE
• Context versus existing drugs. Finasteride’s side-effect profile is well mapped after decades of use and thousands of trial patients. Minoxidil’s topical safety is also well characterized, and even oral minoxidil has growing prospective data in dermatology. VDPHL01 must establish its own risk-benefit profile alongside these benchmarks. FDA Access Data

Until results are posted, the fair summary is: designed to avoid hormonal drawbacks, monitored in a rigorous, blinded program, with safety claims still pending formal readout. ClinicalTrials.gov

Practical questions clinicians and patients will ask

How fast might it work if it works?
Companies sometimes highlight “visible change by two to four months” during conference seasons to build interest. With AGA biology, the earliest objective hair-count improvements typically show around 12 to 24 weeks, with clearer changes by 6 to 12 months, and stabilization beyond that. If VDPHL01 hits that cadence in a large cohort, it would be in line with expectations. We still need the data. PubMed

Who qualifies in the trials?
The male study enrolls healthy men 18 to 65 with mild to moderate AGA. The female study enrolls women with AGA as well. Details like Norwood/Hamilton or Ludwig scales, washout rules, and allowed background therapies are in the fine print of protocols and will matter to interpretability. The public listings confirm age and diagnosis bands and the double-blind design. ClinicalTrials.gov

Will combination therapy be studied?
Most patients in the real world combine treatments. Finasteride or dutasteride for miniaturization pressure, minoxidil for anagen support, PRP or low-level light, and hair-care routines. Whether VDPHL01 is studied as monotherapy first (typical) and then in combinations later is to be seen in subsequent trial phases and any extension phases. The male trial mentions a treatment extension phase, which could supply long-run signals. ClinicalTrials.gov

When might VDPHL01 be available to consumers?

The timeline is gated by trial completion and regulatory review:

• Phase 2/3 execution. A national, 480-patient program across dozens of sites takes time to recruit, treat, and follow. The sponsor had targeted Phase 2 topline in the first half of 2025. Today is Oct 13, 2025, and there is no official topline announcement posted on the company’s news page. That implies either the data are still being prepared for release, were presented at a meeting without a press release, or the timeline shifted. None of that is unusual in drug development. Business Wire
• If Phase 2 is positive. The sponsor could proceed to complete the Phase 3 part of the program and then file an NDA with the FDA. Standard review is about 10 months after a complete filing, with priority reviews shorter. Manufacturing, labeling, and any required safety follow-up can add time. Since no NDA has been filed yet, consumer availability is not imminent. Think in years, not months. Business Wire
• Geography and labeling. Initial approval, if achieved, would likely be for AGA in adults with specific labeling, dosing, and safety guidance. Women’s labeling often takes longer because sex-specific safety considerations can require more data. The existence of a dedicated female AGA trial is a positive sign that the sponsor is pursuing inclusive labeling. ClinicalTrials.gov

Where does this leave VDPHL01 relative to today’s options?

Think of the current landscape as three layers:

1. Proven baselines.
• Finasteride 1 mg daily: robust hair-count gains and slowed loss at 6 to 12 months, maintained over 2 years in large, controlled studies and reflected in the FDA label. This remains the standard oral benchmark in men. FDA Access Data
• Topical minoxidil 5 %: clearly superior to 2 % and placebo in men over 48 weeks, with a long safety record. PubMed
• Oral minoxidil: increasingly used off label in dermatology, but not clearly superior to topical 5 % in a recent randomized trial at 24 weeks. JAMA Network

Emerging entrants, including VDPHL01.

• • VDPHL01 is built to be oral and non-hormonal, aiming to pair convenience with a side-effect profile that avoids the hormonal issues some patients wish to avoid. Efficacy and safety are being tested in the right kind of trials, but publicly posted results are not yet available. ClinicalTrials.gov

Procedural and regenerative add-ons.

• • Hair transplantation, PRP protocols, low-level light therapy, and other adjuncts continue to improve technique and patient selection. No pill obviates surgery for everyone, but better drugs can reduce the slope of loss and preserve grafts. This is the clinical context in which VDPHL01 would live if approved. (Contextual statement, no single source needed.)

Practical guidance right now: if you are losing hair today, you still anchor to proven options while watching the VDPHL01 story. Many patients prefer to combine modalites. For patients who will not use hormonal drugs, a strong non-hormonal oral would be a welcome addition if the data support it.

Key open questions to watch as data emerge

1. Magnitude of hair-count change at 24 to 26 weeks and at 48 to 52 weeks. The absolute delta versus placebo and the responder distribution matter far more than early anecdotes. ClinicalTrials.gov
2. Consistency across scalp regions. Vertex and mid-scalp often respond differently than frontal hairline. Detailed maps will tell us where VDPHL01 shines. (To be answered by the final readout.)
3. Safety profile over 12 to 13 months. Any oral taken daily for a common condition must demonstrate a clean profile over time. The double-blind design is there to surface this. ClinicalTrials.gov
4. Women’s data. AGA in women is under-served. A positive female trial would be a meaningful advance. ClinicalTrials.gov
5. Durability and maintenance. Is there continued improvement after a year, or a plateau, or a need for combination therapy? Long extensions will answer that. ClinicalTrials.gov

Conclusion

VDPHL01 is one of the most closely watched oral candidates in pattern hair loss because it aims for a simple value proposition: a non-hormonal pill designed specifically for AGA. The sponsor has raised substantial capital, registered sound, blinded studies in both men and women, and signaled a large, national Phase 2/3 plan. That is exactly the blueprint you want to see for a therapy that could change day-to-day clinical practice if it hits its targets. Business Wire

At the same time, the public evidence today is still at the “in progress” stage. There is not yet a peer-reviewed, fully detailed dataset showing hair-count deltas, responder rates, or a comprehensive adverse-event table. Without that, it would be premature to declare VDPHL01 “better than” minoxidil 5 % or finasteride 1 mg. The right stance is patient, curious, and evidence-driven. If the Phase 2/3 results are as strong as the program design hopes, VDPHL01 could fill a real gap for the many patients who want an oral option without hormonal trade-offs. Until then, the standard of care remains the proven therapies, plus thoughtful combinations and procedural options tailored to individual goals. FDA Access Data

References and useful links

• Veradermics, clinical-trials page and AGA overview. Company description of VDPHL01 and trial enrollment for a national Phase 2/3 program. Veradermics LIVE
• ClinicalTrials.gov, male AGA study NCT06724614. Multicenter, randomized, double-blind, placebo-controlled design in men 18 to 65 with AGA. ClinicalTrials.gov
• ClinicalTrials.gov, female AGA study NCT07146022. Safety and efficacy evaluation in women with AGA. ClinicalTrials.gov
• CenterWatch listing for NCT06724614, and MedPath trial summary. Third-party descriptions noting the 8.5 mg tablet and multi-visit, 13-month schedule. Use as descriptive context pending sponsor-posted details. CenterWatch
• Veradermics Series B and Phase 2/3 initiation press information, including target of about 480 patients across 44 sites and previously guided Phase 2 topline timing. Business Wire
• New York Post coverage noting paid volunteer testing and the non-hormonal positioning. Trade coverage, not a scientific source, but useful for public sentiment tracking. New York Post
• Reddit r/tressless thread discussing VDPHL01. Community discussion that reflects interest and questions, including mechanism speculation. Not a scientific source. Reddit
• Finasteride efficacy and label data. FDA label for Propecia and peer-reviewed trials showing hair-count differences and anagen shift at 6 to 12 months and beyond. FDA Access Data
• Minoxidil efficacy. Randomized data showing 5 % topical outperforming 2 % and placebo at 48 weeks in men, and a randomized trial finding oral 5 mg daily not superior to topical 5 % at 24 weeks. PubMed
• Additional round-ups and trackers that follow the Veradermics program and timeline expectations. Useful for context, not a substitute for sponsor-posted data. Hair Loss Cure 2020

Medical Disclaimer

This article is for educational, general-information purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Always consult a licensed physician or other qualified healthcare provider before starting, changing, or stopping any medication, supplement, or health regimen – especially if you have a medical condition, take prescription drugs, or have concerns about your health.

Reading this article does not create a physician-patient relationship with the author, editors, contributors, or any affiliated parties.

The authors and publishers disclaim all liability for actions taken or not taken based on this content. You are solely responsible for how you use any information herein, including the proper use of supplements.

Even when recommended dosages are followed, unforeseen side effects can occur; risks cannot be fully eliminated. By using this article, you acknowledge and agree that the authors, editors, and contributors are not liable for any direct, indirect, incidental, or consequential outcomes arising from your reliance on the content.